Evaluation of a Boosting Regimen With Oral Cholera Vaccine

Learn more about:
Related Clinical Trial
Preventative Intervention for Cholera for 7 Days Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults PXVX0200 (CVD103-HgR) vs Shanchol in Mali Cholera-Hospital-Based-Intervention-for-7-days A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi Single Dose Azithromycin in the Treatment of Adult Cholera Safety and Immunogenicity of a New Formulation of Euvichol® Cholera Anti-Secretory Treatment Trial PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Zinc Supplementation in Cholera Patients Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Pilot Introduction of Oral Cholera Vaccine in Orissa, India Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Immunity to Human Cholera in Bangladesh Ciprofloxacin Multiple Dose for Adult Cholera Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo Protective Immunity to Human Cholera in Bangladesh Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Oral Cholera Vaccine Delivery in Rural Bangladesh Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Mass Oral Cholera Vaccination in Zanzibar Cholera Vaccine Investment Strategy in Bangladesh Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Introduction of Cholera Vaccine in Bangladesh Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Evaluation of a Boosting Regimen With Oral Cholera Vaccine Single Dose Azithromycin to Prevent Cholera in Children Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Brief Title

Evaluation of a Boosting Regimen With Oral Cholera Vaccine

Official Title

A Open Labeled Controlled Trial to Evaluate the Immune Response of a Boosting Regimen With Shanchol™, a Killed Whole Cell Oral Cholera Vaccine (WC-OCV), in Previously Immunized Adults and Children in Eastern Kolkata, India

Brief Summary

      Data demonstrates that Shanchol™ (killed bivalent oral cholera vaccine) provides protection
      over 3 years and data regarding the protective efficacy over five years is anticipated for
      2012. Regardless at the end of five years, it may still be necessary to provide a booster
      dose or reimmunize with two doses to maintain protection in previously immunized populations.
      This study examines the immune protection and safety of providing a one and two dose boosting
      regimen of Shanchol™ given five years after the initial dose.
    


Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

Immunogenicity provided by a two dose boosting regimen of Shanchol™

Secondary Outcome

 Immunogenicity provided by a one dose boosting regimen of Shanchol™

Condition

Cholera

Intervention

Shanchol™, oral cholera vaccine

Study Arms / Comparison Groups

 Vaccine to past vaccinated participants
Description:  The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

426

Start Date

December 2012

Completion Date

July 2013

Primary Completion Date

July 2013

Eligibility Criteria

        Inclusion Criteria:

        All subjects must be presently enrolled in the Phase 3 NICED RCT of Shanchol™ and satisfy
        the following criteria at study entry:

          1. Male or female adults aged 6 years and above, who are available for follow-up visits
             and specimen collection.

               -  The subject should be able to continue in the study for the next 6 weeks

               -  The subject (or parent/guardian) should be willing to provide 3 blood samples

          2. Written informed consent obtained from the subjects or their parents/guardians, and
             written assent obtained from children aged 12 - 17 years.

          3. Healthy subjects as determined by:

               -  Medical history

               -  Physical examination

               -  Clinical judgment of the investigator

        Exclusion Criteria:

          1. individuals who are too weak to get out of bed to receive the vaccine

          2. pregnant women (identified through verbal screening)

          3. those less than 6 years of age

          4. Receipt of cholera vaccine following 2009 (time of licensure and availability of
             Shanchol™ in India)
      

Gender

All

Ages

6 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Suman Kanungo, MBBS, , 

Location Countries

India

Location Countries

India

Administrative Informations


NCT ID

NCT01579448

Organization ID

CR-WC-11


Responsible Party

Sponsor-Investigator

Study Sponsor

Sachin Desai

Collaborators

 National Institute of Cholera and Enteric Diseases, India

Study Sponsor

Suman Kanungo, MBBS, Principal Investigator, National Institute of Cholera and Enteric Diseases, India


Verification Date

September 2013